Processa Pharmaceuticals Executive Buys Shares Amid Valuation Signals
David Young, President of Research & Development at Processa Pharmaceuticals, Inc., recently acquired a block of common shares. This buying activity is notable given his direct holdings and the timing relative to upcoming earnings reports, suggesting potential internal belief in the company's current valuation.